SEC Form 4 · accession 0001553878-17-000057
ALNYLAM PHARMACEUTICALS, INC. · ALNY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Dennis A Ausiello
Director
Period of report
Nov 2, 2017
Accepted (ET)
Nov 3, 2017 · 8:14 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001178670
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 2, 2017 | M | 20,000 | $30.09 | A | 20,000 | D | |
| Common Stock | Nov 2, 2017 | S | 20,000 | $130.00 | D | 0 | D | |
| Common StockF2 | holding | — | — | — | 3,500 | I | by Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F3 | $30.09 | Nov 2, 2017 | M | 20,000 | D | — | Jun 6, 2023 | Common Stock | 20,000 | 0 | D |
Explanation of responses
- F1The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 1, 2017.
- F2The shares of ALNY common stock are held in a trust, of which the reporting person's spouse is the trustee.
- F3The stock option will vest as to one third of the shares on each of the first, second and third anniversaries of the date of grant.